The Covid vaccine in the pill prevents severe disease and transmission in preclinical tests

An American research team is developing a new vaccine for Covid that aims to counter the risk of transmission more effectively. How it works.

Turn on notifications to receive updates

new Corona virus vaccine Experimental is administered in Pills or by the way the nose protects from severe illness It reduces the risk of transfer Coronavirus SARS-CoV-2, smashing the diffusion of air. This protects both the recipient of the vaccine and society at large. The new drug has been successfully tested in animal models (hamsters) and is intended to promotemucosal vaccination The respiratory tract, the gateway to the epidemiological pathogen, which will therefore encounter a kind of “barrier” at the entrance and exit, in case revolutionary infection.

The new Covid vaccine was developed by a US research team led by scientists from the Duke Center for Human Immunological Systems at Duke University, who collaborated closely with colleagues from biotech company Vaxart and Lovelace Biomedical Research. Institute of Albuquerque. The scientists, led by Professor Stephanie Engel, a professor in the Department of Surgery at American University, used technology to develop the new vaccine. Type 5 adenovirus vectors (Ad5-vectored), designed to express a file S protein or rise of SARS-CoV-2, the hook that a pathogen uses to bind the ACE-2 receptor to human cells, break the cell wall, pour viral RNA inside and start the replication process that causes disease (COVID-19). The vaccine is designed to be taken orally by pill.

Professor Langel and colleagues tested the candidate vaccine on hamsters, looking for a powerful vaccine antibody response In both the blood and the lungs. After exposing vaccinated hamsters to high levels of SARS-CoV-2 to cause a breakthrough infection, they noticed that animals protected with an adenovirus vaccine had fewer symptoms than those not protected with the vaccine, particularly the lungs. The viral RNA is contagious in both the nose and lower respiratory tract, and little of it is disseminated in the environment. As Professor Langle defined in a press release, a vaccine of this type aimed at immunizing the mucosa stimulates the production of Immunoglobulin A (IgA), the antibody that is the immune system’s “first line of defense against pathogens,” is in both the nose and lungs. She explains that by securing these entrances, it is possible to reduce the possibility that vaccinated people will spread infection by penetrating the virus into the air.

Ancona, 4-year-old girl with Covid dies of respiratory failure: ‘She was seriously ill’

“Our data demonstrate that mucosal immunization is a viable strategy to reduce the spread of COVID through airborne transmission,” said the study’s lead author. In view of the severe circulation of the virus and the risk of reinfection due to mutated strains such as omicron sub variants, having a vaccine that can also reduce transmission and not only the risk of hospitalization/serious illness can be a huge advantage in the fight against the epidemic, especially in areas that are still in which pollination coverage is less than optimal. In a phase I clinical trial, the same vaccine platform released mucosal IgA-reactive immunoglobulin. Details of the research “Oral and intranasal adenovirus type 5 SARS-CoV-2 vaccines to reduce disease severity and transmission in a hamster model” are published in the authoritative scientific journal Science Traslational Medicine.

Leave a Comment